Targeting cell cycle arrest in breast cancer by phytochemicals from Caryto urens L. fruit ethyl acetate fraction: in silico and in vitro validation

IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE
Ghanshyam Parmar, Jay Mukesh Chudasama, Ashish Shah, Chintan Aundhia, Sunil Kardani
{"title":"Targeting cell cycle arrest in breast cancer by phytochemicals from Caryto urens L. fruit ethyl acetate fraction: in silico and in vitro validation","authors":"Ghanshyam Parmar,&nbsp;Jay Mukesh Chudasama,&nbsp;Ashish Shah,&nbsp;Chintan Aundhia,&nbsp;Sunil Kardani","doi":"10.1016/j.jaim.2024.101095","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>Caryota urens</em>, also known as Shivjata, has been documented in ancient Indian texts for its therapeutic benefits, addressing conditions from seminal weakness to gastric ulcers. This study aims to investigate its contemporary medicinal potential in treating breast cancer.</div></div><div><h3>Objectives</h3><div>The study focuses on exploring the therapeutic potential of <em>Caryota urens</em> fruit against breast cancer, specifically targeting cell cycle genes CDK1, CDC25A, and PLK1 through bioinformatics, network pharmacology, and in vitro validation.</div></div><div><h3>Materials and methods</h3><div>Using mass spectrometry and nuclear magnetic resonance (NMR), 60 key phytoconstituents from <em>Caryota urens</em> fruit were identified. Bioinformatics analysis, integrating Gene Cards and GEO databases, 15,474 breast cancer-associated genes focusing on the HR+/HER2-subtype were identified. Molecular docking and qPCR validated the interactions of key phytoconstituents, particularly Episesamin, with CDK1, CDC25A, and PLK1. In vitro studies were conducted on the MCF7 cell line, supplemented by ROC and survival analyses to evaluate diagnostic and therapeutic potential.</div></div><div><h3>Results</h3><div>The bioinformatics analysis identified CDK1, CDC25A, and PLK1 as pivotal genes regulating cell cycle progression and breast cancer tumorigenesis. Network pharmacology and in vitro studies indicated that phytoconstituents, especially Episesamin, downregulated these genes in breast cancer cells. Molecular docking and qPCR confirmed these interactions, and ROC and survival analyses underscored their diagnostic and therapeutic significance.</div></div><div><h3>Conclusions</h3><div>This study suggests that <em>Caryota urens</em> fruit extract, particularly Episesamin, may inhibit breast cancer metastasis by downregulating CDK1, CDC25A, and PLK1, offering promising new strategies for targeting the cell cycle in breast cancer and emphasizing the value of integrating bioinformatics with experimental methods in cancer research.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"16 2","pages":"Article 101095"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ayurveda and Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0975947624002109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Caryota urens, also known as Shivjata, has been documented in ancient Indian texts for its therapeutic benefits, addressing conditions from seminal weakness to gastric ulcers. This study aims to investigate its contemporary medicinal potential in treating breast cancer.

Objectives

The study focuses on exploring the therapeutic potential of Caryota urens fruit against breast cancer, specifically targeting cell cycle genes CDK1, CDC25A, and PLK1 through bioinformatics, network pharmacology, and in vitro validation.

Materials and methods

Using mass spectrometry and nuclear magnetic resonance (NMR), 60 key phytoconstituents from Caryota urens fruit were identified. Bioinformatics analysis, integrating Gene Cards and GEO databases, 15,474 breast cancer-associated genes focusing on the HR+/HER2-subtype were identified. Molecular docking and qPCR validated the interactions of key phytoconstituents, particularly Episesamin, with CDK1, CDC25A, and PLK1. In vitro studies were conducted on the MCF7 cell line, supplemented by ROC and survival analyses to evaluate diagnostic and therapeutic potential.

Results

The bioinformatics analysis identified CDK1, CDC25A, and PLK1 as pivotal genes regulating cell cycle progression and breast cancer tumorigenesis. Network pharmacology and in vitro studies indicated that phytoconstituents, especially Episesamin, downregulated these genes in breast cancer cells. Molecular docking and qPCR confirmed these interactions, and ROC and survival analyses underscored their diagnostic and therapeutic significance.

Conclusions

This study suggests that Caryota urens fruit extract, particularly Episesamin, may inhibit breast cancer metastasis by downregulating CDK1, CDC25A, and PLK1, offering promising new strategies for targeting the cell cycle in breast cancer and emphasizing the value of integrating bioinformatics with experimental methods in cancer research.
从核桃果实乙酸乙酯部分提取的植物化学物质靶向乳腺癌细胞周期阻滞:硅和体外验证
在古印度文献中,也被称为Shivjata的仙人掌具有治疗作用,可以治疗从精液无力到胃溃疡的各种疾病。本研究旨在探讨其治疗乳腺癌的当代医学潜力。目的通过生物信息学、网络药理学和体外验证等方法,探索柚果对细胞周期基因CDK1、CDC25A和PLK1的治疗潜力。材料与方法采用质谱分析和核磁共振(NMR)技术,对柚果中的60种主要植物成分进行了鉴定。通过生物信息学分析,整合Gene Cards和GEO数据库,共鉴定出15474个以HR+/ her2亚型为主的乳腺癌相关基因。分子对接和qPCR验证了关键植物成分,特别是Episesamin与CDK1、CDC25A和PLK1的相互作用。在MCF7细胞系上进行了体外研究,并辅以ROC和生存分析来评估诊断和治疗潜力。结果生物信息学分析发现,CDK1、CDC25A和PLK1是调控细胞周期进程和乳腺癌肿瘤发生的关键基因。网络药理学和体外研究表明,植物成分,特别是Episesamin,在乳腺癌细胞中下调了这些基因。分子对接和qPCR证实了这些相互作用,ROC和生存分析强调了它们的诊断和治疗意义。结论本研究提示,鹿角果提取物,特别是Episesamin,可能通过下调CDK1、CDC25A和PLK1抑制乳腺癌转移,为乳腺癌细胞周期靶向提供了新的策略,强调了生物信息学与实验方法结合在癌症研究中的价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Ayurveda and Integrative Medicine
Journal of Ayurveda and Integrative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
4.70
自引率
12.50%
发文量
136
审稿时长
30 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信